N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells

Matsueda, S; Gao, H; Efferson, CL; Tsuda, N; Ishiyama, S; Li, Y; Ioannides, MG; Fisk, B; Peoples, GE; Ioannides, CG

dc.contributor.author	Matsueda, S	en
dc.contributor.author	Gao, H	en
dc.contributor.author	Efferson, CL	en
dc.contributor.author	Tsuda, N	en
dc.contributor.author	Ishiyama, S	en
dc.contributor.author	Li, Y	en
dc.contributor.author	Ioannides, MG	en
dc.contributor.author	Fisk, B	en
dc.contributor.author	Peoples, GE	en
dc.contributor.author	Ioannides, CG	en
dc.date.accessioned	2014-03-01T01:58:47Z
dc.date.available	2014-03-01T01:58:47Z
dc.date.issued	2009	en
dc.identifier.issn	02507005	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28723
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-69249191545&partnerID=40&md5=8a54341cc83c528220bf2b0755761e87	en
dc.subject	AE-37	en
dc.subject	AE-47	en
dc.subject	Cancer vaccines	en
dc.subject	E75	en
dc.subject	F7	en
dc.subject	Helper effect	en
dc.subject	HER-2	en
dc.subject	High-affinity CD8+ cells	en
dc.subject	p776	en
dc.subject	Perforin	en
dc.subject.other	cancer vaccine	en
dc.subject.other	CD8 antigen	en
dc.subject.other	cell protein	en
dc.subject.other	epidermal growth factor receptor 2	en
dc.subject.other	gamma interferon	en
dc.subject.other	peptide	en
dc.subject.other	peptide ae 37	en
dc.subject.other	peptide ae 47	en
dc.subject.other	perforin	en
dc.subject.other	protein e75	en
dc.subject.other	protein lrmk	en
dc.subject.other	T lymphocyte receptor	en
dc.subject.other	unclassified drug	en
dc.subject.other	article	en
dc.subject.other	breast cancer	en
dc.subject.other	case report	en
dc.subject.other	cell differentiation	en
dc.subject.other	controlled study	en
dc.subject.other	cytotoxic lymphocyte	en
dc.subject.other	human	en
dc.subject.other	immunogenicity	en
dc.subject.other	peripheral blood mononuclear cell	en
dc.subject.other	priority journal	en
dc.subject.other	protein expression	en
dc.subject.other	CD8-Positive T-Lymphocytes	en
dc.subject.other	Cell Differentiation	en
dc.subject.other	Enzyme-Linked Immunosorbent Assay	en
dc.subject.other	Humans	en
dc.subject.other	Lymphocyte Activation	en
dc.subject.other	Peptide Fragments	en
dc.subject.other	Perforin	en
dc.subject.other	Receptor, erbB-2	en
dc.subject.other	Receptors, Antigen, T-Cell	en
dc.title	N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells	en
heal.type	journalArticle	en
heal.publicationDate	2009	en
heal.abstract	The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776-788), respectively, help differentiation of E75-TCR+CD8+ cells. Activation was quantified in terms of proliferation of E75-TCR+CD8+ cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8+ cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8+ cells, in E75-TCR+CD8+ cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75+AE-37 and E75+AE-47 more greatly increased the number of E75-TCRHi CD8+Perf+ cells than PBMCs activated by AE-47 alone or AE-47+ E75. E75 plus cytokines and cytokines alone activated more E75-TCRLow cells than did AE-37 and AE-47. E75+ AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8+ cells from BRC ascites, in allogeneic activation, to Perf+ cells. Preferential differentiation of E75-TCR+CD8+Perf+ cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8+ cells, compared with native, natural HER-2 peptides and/or protects CD8+ cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8+ effectors.	en
heal.journalName	Anticancer Research	en
dc.identifier.volume	29	en
dc.identifier.issue	7	en
dc.identifier.spage	2427	en
dc.identifier.epage	2435	en